ScreenPoint Medical B.V.

ScreenPoint Medical BV delivers innovative artificial intelligence solutions aimed at improving breast cancer detection accuracy. Their flagship product, Transpara, enhances mammography readings through advanced deep learning technology. ScreenPoint Medical BV, founded in 2014 in the Netherlands, specializes in artificial intelligence for breast cancer detection. The company has not undergone any major pivots and does not have any known subsidiaries.

Its CEO, Mark Koeniguer, leads the company as it focuses on integrating AI solutions into clinical workflows. In April 2026, ScreenPoint Medical BV raised USD 14 million in venture funding from Insight Partners and Siemens Medical Solutions USA, Inc. The venture funding was part of a larger USD 16 million venture and grant funding. ScreenPoint Medical specializes in advanced artificial intelligence solutions for breast cancer detection, with its core product being Transpara.

Transpara is a deep learning algorithm designed to enhance the accuracy of mammography readings, specifically for 2D and 3D imaging. The technology assists radiologists by providing risk assessments and improving detection capabilities, especially in patients with dense breast tissue. Released in 2014, Transpara has been integrated into clinical workflows across various healthcare environments, including hospitals and imaging centers in North America and Europe. The company's clientele includes radiologists and healthcare institutions, with a focus on improving patient outcomes through early cancer detection and streamlined screening processes.

ScreenPoint Medical generates revenue primarily through B2B transactions with healthcare providers, offering its Transpara software as a subscription service that integrates into existing imaging workflows. The company's business model emphasizes direct partnerships with hospitals and diagnostic imaging centers, allowing for customized installations and ongoing support. Pricing structures are tailored to client needs and may vary based on the scope of implementation, including training and technical assistance. Transpara, as a flagship product, serves as the central offering in these transactions, enabling healthcare facilities to enhance their mammography services and ultimately improve diagnostic efficiency and patient care.

The company will use the April 2026 funding to support continued product innovation, international expansion, and strategic initiatives that strengthen its position in personalized breast cancer care.